TaiGen Biopharmaceuticals Holdings Ltd (太景醫藥研發控股) last quarter swung into a net loss of NT$102 million (US$3.34 million) due to falling revenue, and high research and development expenses.
That compared with a net profit of NT$60.45 million in the second quarter on the back of a one-time milestone payment of US$5 million for its hepatitis C drug Furaprevir.
However, last quarter’s losses contracted 17 percent from a year earlier thanks to a 36 percent decline in non-operating costs to NT$36.76 million, the Taipei-based company said.
Revenue fell 3 percent from a year earlier to NT$4.79 million during the July-to-September period, as sales of its oral formulation of antibiotic Taigexyn, used for pneumonia treatment, slowed down due to fewer patients in the hot season, TaiGen told an investors’ conference in Taipei on Tuesday.
Net losses totaled NT$96.37 million in the first three quarters of this year, down 61 percent from net losses of NT$247 million a year earlier, company data showed.
Losses per share were NT$0.13, compared with NT$0.35 a year earlier.
TaiGen said sales of Taigexyn would rebound this quarter, as pneumonia cases are expected to increase over the winter.
Revenue last month rose 2.4 times annually to NT$5.5 million, thanks to massive purchases of the drug by its local marketing partner, Holding Disp Co Ltd (文德藥業), TaiGen said.
“Overall, the sale of Taigexyn posted rapid growth in China and in Taiwan this year, but there is still a cap on the drug’s sales, as it has not been included in the public health insurance program in China,” Taigen chairman Philip Huang (黃國龍) said.
The company has negotiated with Chinese regulators to have Taigexyn included in the insurance program and is awaiting their decision, Huang said.
The drug last year was added to the National Health Insurance program.
As for the intravenous formulation of Taigexyn, which TaiGen has said would be more popular and profitable than the oral formulation, the firm reiterated that it could start selling the drug in China next year, as it expects to gain marketing approval soon.
Meanwhile, TaiGen has submitted a pre-investigational new drug application to the Chinese National Medical Products Administration for its new anti-influenza drug TG-1000, Huang said.
The new drug would be a more effective treatment than the anti-flu drug oseltamivir, which is sold under the brand name Tamiflu, as people can take TG-1000 within 72 hours of the onset of symptoms, while Tamiflu has to be taken within 48 hours, Huang said.
If the new drug’s application and clinical trials proceed smoothly, it could obtain marketing approval in three to four years, he added.
NOTABLE SHIFT: By 2030, 50% of all laptops would be assembled in Southeast Asia, while Taiwan would still mostly focus on research and development, a report said Global laptop and desktop computer supply chains are expected to shift significantly away from China in the next 10 years, a Market Intelligence & Consulting Institute (MIC, 產業情報研究所) report said. By 2030, only 40 percent of global laptop production would remain in China, said the report, which was released on Thursday. “The reshuffling of the global supply chain will be one of the most important trends in the next 10 years,” the institute said in the report. “In the long run, key component makers will follow laptop assemblers in moving out of China.” The Taipei-based institute predicted most key component makers
Merck Group Taiwan yesterday said that it plans to invest substantially on expanding its fab in Kaohsiung’s Lujhu District (路竹) to better serve its local customers, including Taiwan Semiconductor Manufacturing Co (TSMC, 台積電). The company said it plans to expand its production space by 50 percent in the next five years and its workforce by about 40 percent, Merck Group Taiwan managing director Dick Hsieh (謝志宏) told a media briefing in Taipei. Hsieh declined to disclose investment details, but said that the latest investment would exceed the total amount Merck has invested in Taiwan over the past few years. Those investments would be
INVEST IN TAIWAN: A metal components casting firm and the world’s largest maker of aluminum bicycle rims also obtained approvals to join the program Solar Applied Materials Technology Co (SOLAR, 光洋應用材料), a part of Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) “green supply chain,” has pledged to invest NT$1 billion (US$34.1 million) to build a new plant at the Tainan Technology Industrial Park (台南科技工業區), the Ministry of Economic Affairs said yesterday. SOLAR has been collaborating with TSMC to extract precious metals from waste and reuse them as “sputtering target” material in high-end semiconductor manufacturing, a TSMC press release issued in May said. Established in 1978, SOLAR also offers key materials and integrated services to customers in the optoelectronics, information and communications technology, petrochemicals and consumer electronics industries,
‘SWARM TECH’: Joint venture FARobot is to develop autonomous mobile robots that would first be deployed in Hon Hai’s factories to optimize production efficiency Hon Hai Precision Industry Co (鴻海精密) and Adlink Technology Inc (凌華科技) have formed a robotic venture that aims to use “swarm technology” to create robots that can communicate with one another on the factory floor to optimize production efficiency. Hon Hai is Apple Inc’s leading iPhone assembler and the world’s largest contract electronics maker, while Adlink supplies industrial computers and Internet of Things solutions. Through a subsidiary, Hyield Venture Capital Co (鴻揚創投), Hon Hai holds a 51 percent stake in autonomous mobile robot (AMR) developer FARobot (法博智能移動), while Adlink owns the remaining 49 percent. Together, the two companies put up NT$200